340B HCV Program

Hepatitis C Treatment Network

Sheila Reynoso, MPH
Director
Outline

- Background of 340B program
- Background of HCV program
- Implementation of HCV 340B Program
- Recommendations
Background – HCV Program

- CMS Grant – Project INSPIRE
  - INSPIRE - Innovate & Network to Stop HCV & Prevent complications via Integrating care, Responding to needs and Engaging patients & providers
  - Program Period: September 1st, 2014 – August 31st, 2017 (3 years)
  - Geographic Reach: Upper Manhattan and Bronx
  - Funding Amount: $9,948,459 (Montefiore $3,500,000)
Background – 340B Program

- Created as part the Social Security Act and in 1992 Section 340B was added.
- Purpose is to enables covered entities to stretch scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.
- Covered Entity is approved by HRSA to purchase medications at highly reduced cost for Outpatient use.
- At Montefiore HCV drugs are purchased at 340B prices and the savings are applied to providing more resources for providing care to our patients.
- Many rules, regulations and requirements
- Hot topic in Congress.
HCV 340B Program Implementation

• 06/16: Proposal to Montefiore leadership
• 01/17: Program approved by leadership
• 02/17: First HCV prescription sent to Montefiore Outpatient Pharmacy
• 06/17: Approval of funding for HCV Treatment Network
• 06/17-09/17: Transition of HCV Program
• 09/17 - Present: All approved HCV meds filled at Montefiore Outpatient Pharmacy
06/16 – 06/17
Proposal to Montefiore leadership

• Understanding the 340B program
• Working with Montefiore Pharmacy
• Meetings with Montefiore leadership
  – Chief, Division of General Internal Medicine
  – Chair, Department of Medicine
  – Director of Pharmacy
  – Montefiore Medical Group Leadership
  – Vice President of Clinical Operations
Pre-INSPIRE
Post-INSPIRE
Type of Insurance Coverage for INSPIRE Patients

Figure 2. Percent of INSPIRE Enrollees by Insurance (N=1806)

- Medicaid MCO: 431 (29%)  
- Healthfirst: 113 (8%)  
- VNSNY: 113 (8%)

Legend:
- Medicaid
- Medicare
- Dually Eligible (Medicaid + Medicare)
HCV Medication Regimens

- Sofosbuvir +/- Simeprevir +/- Ribavirin: 6% 7%
- Harvoni +/- Ribavirin: 4%
- Viekira Pak: 1%
- Daclatasvir +/- Ribavirin: 6%
- Zepatier +/- Ribavirin: 6%
- Epclusa: 76%

Montefiore
02/17: First HCV prescriptions sent to Montefiore Outpatient Pharmacy

![Graph showing the average margin and total 340b eligible for February to June.]
06/17: Approval of HCV Treatment Network

- HCV Treatment Network will receive a % of 340B HCV savings
- Proposed budget to begin 9/1/2017
06/17-09/17: Transition of HCV Program

- Capacity of Montefiore Pharmacy
- HCV Providers
- Care Coordination support at sites
09/17 - Present
All approved HCV meds are filled at Montefiore Pharmacy

Care Coordination Services
• Prior authorization
• Adherence support
• Pharmacy coordination
• Appointment assistance

340B Pharmacy Services
• Co-Pay Assistance
• Medication Delivery
• Medication Storage

Monitoring
• Pharmacy Database
• Ineligible Prescriptions
• 340B Program
340B Resources

• Apexus 340B Prime Vendor Program
  – www.340bpvp.com
Thank you!!

Hepatitis C Treatment Network
Sheila Reynoso, Director
1-844-CURE-HCV